{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T21:07:20Z","timestamp":1774818440499,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"DOI":"10.7759\/cureus.55251","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:00:22Z","timestamp":1709226022000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Rifaximin Alone and With Quinolones in the Primary Prevention of Spontaneous Bacterial Peritonitis in Patients With Decompensated Chronic Liver Disease"],"prefix":"10.7759","author":[{"given":"Tahir","family":"Zaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Bilal","family":"Ahmed Attari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ahsan","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Aeman","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05943-6","article-title":"Bacterial infection in patients with cirrhosis: don't get bugged to death","volume":"65","author":"Cannon MD","year":"2020","unstructured":"Cannon MD, Martin P, Carrion AF. Bacterial infection in patients with cirrhosis: don't get bugged to death. Dig Dis Sci. 2020, 65:31-7. 10.1007\/s10620-019-05943-6","journal-title":"Dig Dis Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693652","article-title":"An epidemiological meta-analysis on the worldwide prevalence, resistance, and outcomes of spontaneous bacterial peritonitis in cirrhosis","volume":"8","author":"Tay PW","year":"2021","unstructured":"Tay PW, Xiao J, Tan DJ, et al.. An epidemiological meta-analysis on the worldwide prevalence, resistance, and outcomes of spontaneous bacterial peritonitis in cirrhosis. Front Med (Lausanne). 2021, 8:693652. 10.3389\/fmed.2021.693652","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14740\/gr1255","article-title":"Fungal infection in acutely decompensated cirrhosis patients: value of model for end-stage liver disease score","volume":"13","author":"Habib S","year":"2020","unstructured":"Habib S, Yarlagadda S, Carreon TA, Schader LM, Hsu CH. Fungal infection in acutely decompensated cirrhosis patients: value of model for end-stage liver disease score. Gastroenterology Res. 2020, 13:199-207. 10.14740\/gr1255","journal-title":"Gastroenterology Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11010031","article-title":"Antibiotics and liver cirrhosis: what the physicians need to know","volume":"11","author":"Zoratti C","year":"2021","unstructured":"Zoratti C, Moretti R, Rebuzzi L, et al.. Antibiotics and liver cirrhosis: what the physicians need to know. Antibiotics (Basel). 2021, 11:31. 10.3390\/antibiotics11010031","journal-title":"Antibiotics (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002279","article-title":"Incidence of spontaneous bacterial peritonitis among asymptomatic cirrhosis patients undergoing outpatient paracentesis: a systematic review and meta-analysis","volume":"33","author":"Alotaibi A","year":"2021","unstructured":"Alotaibi A, Almaghrabi M, Ahmed O, et al.. Incidence of spontaneous bacterial peritonitis among asymptomatic cirrhosis patients undergoing outpatient paracentesis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021, 33:e851-7. 10.1097\/MEG.0000000000002279","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref6","article-title":"A Study on Estimating Prevalence of Spontaneous Bacterial Peritonitis in Asymptomatic Outpatients With Cirrhotic Ascites undergoing Therapeutic Tapping","author":"Subitha S","unstructured":"Subitha S. A Study on Estimating Prevalence of Spontaneous Bacterial Peritonitis in Asymptomatic Outpatients With Cirrhotic Ascites undergoing Therapeutic Tapping. Coimbatore Medical College, Coimbatore;"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/livers2030018","article-title":"Spontaneous bacterial peritonitis in decompensated liver cirrhosis\u2014a literature review","volume":"6","author":"Huang CH","year":"2022","unstructured":"Huang CH, Lee CH, Chang C. Spontaneous bacterial peritonitis in decompensated liver cirrhosis\u2014a literature review. Livers. 2022, 6:214-32. 10.3390\/livers2030018","journal-title":"Livers"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.29309\/TPMJ\/2020.27.03.968","article-title":"Frequency of spontaneous bacterial peritonintis in chronic liver disease patients using proton pump inhibitors","volume":"10","author":"Khan TU","year":"2020","unstructured":"Khan TU, Khan W, Iqbal S. Frequency of spontaneous bacterial peritonintis in chronic liver disease patients using proton pump inhibitors. Prof Med J. 2020, 10:455-60. 10.29309\/TPMJ\/2020.27.03.968","journal-title":"Prof Med J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.93440","article-title":"Acute on chronic liver failure: role of the bacterial infections","author":"Borzio M","year":"2020","unstructured":"Borzio M, Dionigi E. Acute on chronic liver failure: role of the bacterial infections. Liver Pathology. Gayam V, Engin O (ed): IntechOpen, London; 2020. 10.5772\/intechopen.93440"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124821","article-title":"Bacterial growth and ceftriaxone activity in individual ascitic fluids in an in vitro model of spontaneous bacterial peritonitis","volume":"14","author":"van Os W","year":"2023","unstructured":"van Os W, Wulkersdorfer B, Eberl S, et al.. Bacterial growth and ceftriaxone activity in individual ascitic fluids in an in vitro model of spontaneous bacterial peritonitis. Front Pharmacol. 2023, 14:1124821. 10.3389\/fphar.2023.1124821","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06727-6","article-title":"ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial","volume":"23","author":"Crocombe D","year":"2022","unstructured":"Crocombe D, Ahmed N, Balakrishnan I, et al.. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial. Trials. 2022, 23:812. 10.1186\/s13063-022-06727-6","journal-title":"Trials"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.04.010","article-title":"Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis","volume":"19","author":"Mattos AA","year":"2020","unstructured":"Mattos AA, Wiltgen D, Jotz RF, Dornelles CM, Fernandes MV, Mattos \u00c2Z. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol. 2020, 19:451-7. 10.1016\/j.aohep.2020.04.010","journal-title":"Ann Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i5.239","article-title":"Systemic review and network meta-analysis: prophylactic antibiotic therapy for spontaneous bacterial peritonitis","volume":"12","author":"Faust N","year":"2020","unstructured":"Faust N, Yamada A, Haider H, Komaki Y, Komaki F, Micic D, Sakuraba A. Systemic review and network meta-analysis: prophylactic antibiotic therapy for spontaneous bacterial peritonitis. World J Hepatol. 2020, 12:239-52. 10.4254\/wjh.v12.i5.239","journal-title":"World J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12788\/jfp.0186","article-title":"A guide to diagnosing and managing ascites in cirrhosis","volume":"70","author":"Faisal MS","year":"2021","unstructured":"Faisal MS, Singh T, Amin H, Esfeh JM. A guide to diagnosing and managing ascites in cirrhosis. J Fam Pract. 2021, 70:174-81. 10.12788\/jfp.0186","journal-title":"J Fam Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins SW","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G, et al.. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021, 74:1014-48. 10.1002\/hep.31884","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.04.021","article-title":"Overview of complications in cirrhosis","volume":"12","author":"Premkumar M","year":"2022","unstructured":"Premkumar M, Anand AC. Overview of complications in cirrhosis. J Clin Exp Hepatol. 2022, 12:1150-74. 10.1016\/j.jceh.2022.04.021","journal-title":"J Clin Exp Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100785","article-title":"Use of albumin infusion for cirrhosis-related complications: an international position statement","volume":"5","author":"Bai Z","year":"2023","unstructured":"Bai Z, M\u00e9ndez-S\u00e1nchez N, Romeiro FG, et al.. Use of albumin infusion for cirrhosis-related complications: an international position statement. JHEP Rep. 2023, 5:100785. 10.1016\/j.jhepr.2023.100785","journal-title":"JHEP Rep"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.5152\/tjg.2015.7782","article-title":"The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients","volume":"26","author":"Mostafa T","year":"2015","unstructured":"Mostafa T, Badra G, Abdallah M. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. Turk J Gastroenterol. 2015, 26:163-9.","journal-title":"Turk J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.116232","article-title":"How to calculate sample size for different study designs in medical research?","volume":"35","author":"Charan J","year":"2013","unstructured":"Charan J, Biswas T. How to calculate sample size for different study designs in medical research?. Indian J Psychol Med. 2013, 35:121-6. 10.4103\/0253-7176.116232","journal-title":"Indian J Psychol Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030443","article-title":"Diverticular disease and rifaximin: an evidence-based review","volume":"12","author":"Piccin A","year":"2023","unstructured":"Piccin A, Gulotta M, di Bella S, Martingano P, Croc\u00e8 LS, Giuffr\u00e8 M. Diverticular disease and rifaximin: an evidence-based review. Antibiotics (Basel). 2023, 12:443. 10.3390\/antibiotics12030443","journal-title":"Antibiotics (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00039-23","article-title":"The potential for development of clinically relevant microbial resistance to rifaximin-\u03b1: a narrative review","volume":"36","author":"DuPont HL","year":"2023","unstructured":"DuPont HL. The potential for development of clinically relevant microbial resistance to rifaximin-\u03b1: a narrative review. Clin Microbiol Rev. 2023, 36:e0003923. 10.1128\/cmr.00039-23","journal-title":"Clin Microbiol Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/01480545.2023.2240036","article-title":"Long-term toxicity of fluoroquinolones: a comprehensive review","author":"Hussen NH","year":"2023","unstructured":"Hussen NH, Qadir SH, Rahman HS, Hamalaw YY, Kareem PS, Hamza BA. Long-term toxicity of fluoroquinolones: a comprehensive review. Drug Chem Toxicol. 2023, 1-12. 10.1080\/01480545.2023.2240036","journal-title":"Drug Chem Toxicol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/neurosci2030017","article-title":"Fluoroquinolones-associated disability: it is not all in your head","volume":"16","author":"Freeman MZ","year":"2021","unstructured":"Freeman MZ, Cannizzaro DN, Naughton LF, Bove C. Fluoroquinolones-associated disability: it is not all in your head. NeuroSci. 2021, 16:235-53. 10.3390\/neurosci2030017","journal-title":"NeuroSci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11401774","article-title":"Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence","volume":"4","author":"Flamm SL","year":"2011","unstructured":"Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol. 2011, 4:199-206. 10.1177\/1756283X11401774","journal-title":"Therap Adv Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen KD","year":"2014","unstructured":"Mullen KD, Sanyal AJ, Bass NM, et al.. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014, 12:1390-7.e2. 10.1016\/j.cgh.2013.12.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093909","article-title":"Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites","volume":"9","author":"Lutz P","year":"2014","unstructured":"Lutz P, Parcina M, Bekeredjian-Ding I, et al.. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One. 2014, 9:e93909. 10.1371\/journal.pone.0093909","journal-title":"PLoS One"},{"key":"ref27","article-title":"Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis","volume":"1","author":"M\u00fccke MM","year":"2020","unstructured":"M\u00fccke MM, M\u00fccke VT, Graf C. Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis. Age. 2020, 1:1-5.","journal-title":"Age"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182506dbb","article-title":"The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis","volume":"46","author":"Hanouneh MA","year":"2012","unstructured":"Hanouneh MA, Hanouneh IA, Hashash JG, et al.. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012, 46:709-15. 10.1097\/MCG.0b013e3182506dbb","journal-title":"J Clin Gastroenterol"},{"key":"ref29","article-title":"The role of rifaximine in the prevention of the spontaneous bacterial peritonitis","volume":"117","author":"D\u0103nulescu RM","year":"2013","unstructured":"D\u0103nulescu RM, Ciobic\u0103 A, Stanciu C, Trifan A. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis. Rev Med Chir Soc Med Nat Iasi. 2013, 117:315-20.","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos J","year":"2009","unstructured":"Vlachogiannakos J, Saveriadis AS, Viazis N, et al.. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009, 29:992-9. 10.1111\/j.1365-2036.2009.03958.x","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231069-comparison-of-rifaximin-alone-and-with-quinolones-in-the-primary-prevention-of-spontaneous-bacterial-peritonitis-in-patients-with-decompensated-chronic-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:00:29Z","timestamp":1709226029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231069-comparison-of-rifaximin-alone-and-with-quinolones-in-the-primary-prevention-of-spontaneous-bacterial-peritonitis-in-patients-with-decompensated-chronic-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.55251","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}